DOTmed January 3, 2025
RA Capital Management has announced the completion of AbbVie’s $1.4 billion acquisition of Aliada Therapeutics, a portfolio company founded and supported by RA Capital’s healthcare incubator, Raven.
The deal marks the second major acquisition of a Raven-backed company this year, following Novartis’ $1 billion purchase of Mariana Oncology in May.
Aliada’s lead asset, ALIA-1758, is an investigational anti-pyroglutamate amyloid beta (3pE-Aβ) antibody targeting Alzheimer’s disease. The drug leverages a proprietary blood-brain barrier-crossing technology designed to enhance central nervous system drug delivery. ALIA-1758 is currently undergoing a Phase 1 clinical trial.
Aliada was cofounded in 2021 by Johnson & Johnson Innovation – JJDC, RA Capital, and Raven. The startup was...
Today's Sponsors
Today's Sponsor